New Research on Interstitial Lung Disease Reveals Effective Treatment

Strategic Insights -

Researchers at Osaka Habikino Medical Center in Japan have conducted a study to investigate the efficacy and risks of treating advanced lung cancer complicated by idiopathic interstitial pneumonia (IIP). The study, published in the journal Medical Oncology, found that a combination of chemotherapy agents, carboplatin and paclitaxel, showed a promising response rate of 45.7% in patients with advanced squamous cell lung cancer and IIP.

Key Takeaways:

  • The study involved 35 patients who underwent chemotherapy with carboplatin and paclitaxel, and the response rate was 45.7% (16 patients achieved complete or partial response, 15 patients had stable disease, and 3 patients experienced disease progression).
  • The median overall survival was 9.99 months, and the progression-free survival was 5.75 months.
  • The acute exacerbation rate of IIP was 8.6% (3 patients out of 35 experienced exacerbation).
  • The researchers concluded that the risk factors of acute exacerbation remain to be investigated.
  • The study suggests that carboplatin and paclitaxel is a promising therapy for advanced squamous cell lung cancer with IIP, but the risk of acute exacerbation should be carefully monitored.

Statistics:

  • 45.7% response rate in patients with advanced squamous cell lung cancer and IIP.
  • Median overall survival of 9.99 months.
  • Progression-free survival of 5.75 months.
  • Acute exacerbation rate of IIP of 8.6% (3/35 patients).
  • 11 patients had idiopathic pulmonary fibrosis, 7 had combined pulmonary fibrosis and emphysema, 16 had unclassified IIP, and 1 had interstitial linear abnormality.

Sources:

  • Phase II study of carboplatin + weekly paclitaxel for advanced lung squamous cell carcinoma with idiopathic interstitial pneumonia (Hanshin Cancer Group IP001). Medical Oncology, 2025;42(8):304.
  • Osaka Habikino Medical Center. [www.osakahabikinomedicalcenter.com](http://www.osakahabikinomedicalcenter.com)
  • Hidekazu Suzuki, Dept. of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino city, Osaka, 583-8588, Japan.